Evaluation of a Dimeric Inhibin-A Assay for Assessing Fetal Down Syndrome: Establishment, Comparison, and Monitoring of Median Concentrations for Normal Pregnancies

Archives of Pathology and Laboratory Medicine

Volumn 128, Issue 4, 2004, Pages 415-420

  Erickson, J Alan ^a,c   Ashwood, Edward R ^a,b   Gin, Cynthia A ^c  

^a ARUP INSTITUTE FOR CLINICAL AND EXPERIMENTAL PATHOLOGY   (United States)

^b UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

^c ARUP LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

DIMERIC INHIBIN A; INHIBIN A; UNCLASSIFIED DRUG;

ARTICLE; DIAGNOSTIC ACCURACY; DOWN SYNDROME; ENZYME LINKED IMMUNOSORBENT ASSAY; GESTATIONAL AGE; HUMAN; MAJOR CLINICAL STUDY; MATERNAL SERUM; NORMAL VALUE; PRENATAL DIAGNOSIS; PROTEIN DETERMINATION; RELIABILITY; SCREENING TEST;

ALPHA-FETOPROTEINS; BIOLOGICAL MARKERS; CHORIONIC GONADOTROPIN; DIMERIZATION; DOWN SYNDROME; ENZYME-LINKED IMMUNOSORBENT ASSAY; ESTRIOL; FEMALE; FETAL DISEASES; GESTATIONAL AGE; HUMANS; INHIBINS; PREDICTIVE VALUE OF TESTS; PREGNANCY; PREGNANCY TRIMESTER, SECOND; PRENATAL DIAGNOSIS; REAGENT KITS, DIAGNOSTIC; REFERENCE VALUES; REPRODUCIBILITY OF RESULTS;

EID: 1842479361     PISSN: 00039985     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (27)

1. Ying SY. Inhibins, activins and follistatins: gonadal proteins modulating the secretion of follicle-stimulating hormone. Endocrine Rev 198B;9:267-293.
2. McLachlan RI, Healy DL, Lutjen PJ, Findlay IK, de Krester DM, Burger HG. The maternal ovary is not the source of circulating inhibin levels during human pregnancy. Clin Endocrinol. 1987;27:663-668.
3. Muttukrishna S, Child TJ, Groome NP, Ledger WL. Source of circulating levels of inhibin A, pro alpha C-containing inhibins and activin A in early pregnancy. Hum Reprod. 1997;12:1089-1093.
4. Wald NJ, Densem JW, George L, Muttukrishna S, Knight PG. Prenatal screening for Down's syndrome using inhibin-A as a serum marker. Prenat Diagn. 1996;16:143-153.
5. Riley SC, Wathen NC, Chard T, Groome NP, Wallace EM. Inhibin in extraembryonic coelomic and amniotic fluids and maternal serum in early pregnancy. Hum Reprod 1996;11:2772-2776.
6. Spencer K, Wallace EM, Ritoe S. Second-trimester dimeric inhibin-A in Down's syndrome screening. Prenat Diagn. 1996;16:1101-10.
7. Aitken DA, Wallace EM, Crossley JA, et al. Dimeric inhibin A as a marker for Down's syndrome in early pregnancy. N Engl J Med. 1996;334:1231-1236.
8. Wenstrom KD, Owen J, Chu DC, Boots L. Elevated second-trimester dimeric inhibin A levels identify Down syndrome pregnancies. Am J Obstet Gynecol. 1997;177:992-996.
9. Haddow JE, Palomaki GE, Knight GJ, Foster DL, Neveux LM. Second trimester screening for Down's syndrome using maternal serum dimeric inhibin A. J Med Screen. 1998;5:115-119.
10. Benn PA, Fang M, Egan JF, Horne D, Collins R. Incorporation of inhibin-A in second-trimester screening for Down syndrome. Obstet Gynecol. 2003;101:451-454.
11. Wenstrom KD, Chu DC, Owen J, Boots L. Maternal serum α-fetoprotein and dimeric inhibin A detect aneuploidies other than Down syndrome. Am J Obstet Gynecol. 1998;179:966-970.
12. Lambert-Messerlian GM, Saller DN, Tumber MB, French CA, Peterson CJ, Canick JA. Second-trimester maternal serum inhibin A levels in fetal trisomy 18 and Turner syndrome with and without hydrops. Prenat Diagn. 1998;18:1061-1067.
13. Wenstrom KD, Owen J, Chu DC, Boots L. Prospective evaluation of free β-subunit of human chorionic gonadotropin and dimeric inhibin A for aneuploidy detection. Am J Obstet Gynecol, 1999;1B1:887-892.
14. Benn PA, Gainey A, Ingardia CJ, Rodis JF, Egan JF. Second trimester maternal serum analytes in triploid pregnancies: correlation with phenotype and sex chromosome complement. Prenat Diagn. 2001;21:680-686.
15. Watanabe H, Hamada H, Yamada N, et al. Second-trimester maternal pregnancy associated plasma protein a and inhibin A levels in fetal trisomies. Fetal Diagn Ther. 2002;17:137-141.
16. Spencer K, Wood PJ, Anthony FW. Elevated levels of maternal serum inhibin immunoreactivity in second trimester pregnancies affected by Down's syndrome. Ann Clin Biochem. 1993;30:219-220.
17. Chuckle HS, Holding S, Jones R. Maternal serum inhibin levels in second trimester Down's syndrome pregnancies. Prenat Diagn. 1994;14:387-390.
18. Groome NP, Hancock J, Betteridge A, Lawrence M, Craven R. Monoclonal and polyclonal antibodies reactive with the 1-32 amino terminal peptide of the alpha subunit of human inhibin. Hybridoma, 1990;9:31-42.
19. Groome NP, Lawrence M. Preparation of monoclonal antibodies reactive with the beta A subunit of human ovarian inhibin. Hybridoma. 1991;109:309-316.
20. Groome NP, O'Brian M. Immunoassays for inhibin and its subunits: further applications of the synthetic peptide approach. J Immunol Methods. 1993;165:167-176.
21. Groome NP, Illingworth PJ, O'Brian M, et al. Detection of dimeric inhibin throughout the human menstrual cycle by two-site enzyme immunoassay. Clin Endocrinol. 1994;40:717-723.
22. Knight GJ, Palomaki GE, Neveux LM, Haddow JE, Lambert-Messerlian GM. Clinical validation of a new dimeric inhibin A assay suitable for second trimester Down's syndrome screening. J Med Screen. 2001;8:2-7.
23. MacRae AR, Allen LC, Lepage N, Tokmakejian S. Validation of automated dimeric inhibin-A assay in maternal serum screening for Down syndrome. Clin Chem. 2001;47:A150.
24. Watt HC, Wald NJ, George L. Maternal serum inhibin-A levels in twin pregnancies: implications for screening for Down's syndrome. Prenat Diagn. 1996;16:927-929.
25. Watt PC, Wald NJ, George L. Maternal serum inhibin-A in pregnancies with insulin-dependent diabetes mellitus: implications for screening for Down's syndrome. Prenat Diagn. 1996;16:923-926.
26. Wallace EM, Crossley JA, Savitri CR, Groome NP, Aitken DA. Maternal serum inhibin-A in pregnancies complicated by insulin dependent diabetes mellitus. Br J Obstet Gynecol. 1997;104:946-948.
27. Watt HC, Wald NJ, Smith D, Kennard A, Densem J. Effect of allowing for ethnic group in prenatal screening for Down's syndrome. Prenat Diagn. 1996;16:691-698.